Intercept Pharmaceuticals (ICPT)

[IPO$]

$110 puts expiring next Friday have a big spread at $.65 by $2.70 now after the stock went up $1. makes no sense.

[IPO$]

$110 puts expiring next Friday have a big spread at $.40 by $2.65.

[Anthropoid]

today news - digestive microbiota treat liver diseases.

next , syn bio microbiota drug delivery .

[osaffer]

Look at this:
http://www.globenewswire.com/news-release/2016/02/25/814196/0/en/New-Emergence-of-Potential-Tx-Dx-Options-could-transform-the-35-Billion-Landscape-for-Liver-Diseases-NASH.html

GFT505 is efficient ... and they have the biomarkers

[osaffer]

ICPT is game over, dont deny that

Genfit is number one in the Nash, the publication in Gastroenterology demonstrates the efficiency of Genfit against Nash.

ICPT has NOT yet started the recruitment of patient for Phase 3, during Conference call, CEO was not able to give a date, and so, ICPT has received the green light for Phase 3 a long time before Genfit ... While for Genfit is totally different .

If I were you, I will buy Genfit while the price is still so low.

Most of Analyst decrease the conscensus of ICPT, when the US Analyst will enforce their projection on Genfit, the price will rise rapidly ...

Fundamentals are strong with Genfit, no doubt on that, publication is there, with all experts of Nash ...

Even Adam Feuerstein, big, defender of ICPT cannot attack Genfit anymore ...

Things are changing ... take the good train ...

[osaffer]

http://www.sfgate.com/business/article/Intercept-Pharmaceuticals-sale-carries-big-risk-6834997.php?cmpid=twitter-desktop

[nyctraydr]

Movers and Shakers in Biotech: The Week so Far - article discusses Intercept
http://marketexclusive.com/2957-2/2957/

[harry crumb]

great post with that info. we read it prior, very interesting an gild could be the one

[harry crumb]

we own a few so this could make some serious cash

[north40000]

ICPT: The link:

http://www.reuters.com/article/us-intercept-m-a-exclusive-idUSKCN0VL1ZC

Reference to it was in my TDA mobile news. WSJ short link also there.

GILD on the other side? See its incoming CEO Milligan's comments in Q&A during 4th Qtr earnings call re interest/focus on aspects of liver disease:

"... We're very interested in liver diseases, so that's a very important area for us, and we'll continue to try to bolster those to make sure that the company has the assets necessary to have the progress for the future."

[harry crumb]

yes yes yes, had a hunch a sale could happen with this. not a large position, but some nice green here. gl everybody, sell or wait for 130's

[DewDiligence]

PDUFA date for PBC extended 3 months: #msg-119252133.

[osaffer]

Why GNFT will take the Nash market
http://www.scribd.com/doc/293335048/The-Big-Picture-For-Genfit-NASH-diabetes-CVD

[DewDiligence]

ICPT starts phase-2 trial of OCA + Lipitor: #msg-118982377.

[oldsport]

no effect on stock whatsoever...

[osaffer]

Genfit Phase 3 Approved Breakthroug: 1800 Patients
Genfit on market in 2019 !

[DewDiligence]

Fibrosis-biomarker data from FLINT (presented at AASLD): #msg-118502898.

[oldsport]

buy rumor sell news...

[stocktrademan]

$ICPT recent news/filings

bullish 190.10
double bottom

## source: finance.yahoo.com

Thu, 12 Nov 2015 13:07:12 GMT ~ BioCryst and Intercept Drive Biotechnology Subgroup


read full: http://finance.yahoo.com/news/biocryst-intercept-drive-biotechnology-subgroup-130712709.html
*********************************************************

Mon, 09 Nov 2015 18:31:49 GMT ~ Edited Transcript of ICPT earnings conference call or presentation 9-Nov-15 1:00pm GMT


read full: http://finance.yahoo.com/news/edited-transcript-icpt-earnings-conference-183149861.html
*********************************************************

Mon, 09 Nov 2015 13:55:01 GMT ~ Intercept (ICPT) Posts Narrower-Than-Expected Loss in Q3


read full: http://finance.yahoo.com/news/intercept-icpt-posts-narrower-expected-135501407.html
*********************************************************

Mon, 09 Nov 2015 13:07:11 GMT ~ Myriad Genetics: Top Performer in the Biotechnology Subgroup


read full: http://finance.yahoo.com/news/myriad-genetics-top-performer-biotechnology-130711444.html
*********************************************************

Mon, 09 Nov 2015 12:36:38 GMT ~ INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements


read full: http://biz.yahoo.com/e/151109/icpt8-k.html
*********************************************************

$ICPT charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ICPT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ICPT/company-info
Ticker: $ICPT
OTC Market Place: Not Available
CIK code: not found
Company name: Intercept Pharmaceuticals, Inc.
Incorporated In:

Business Description:

$ICPT share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$ICPT extra dd links

Company name: Intercept Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ICPT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ICPT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ICPT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ICPT/news - http://finance.yahoo.com/q/h?s=ICPT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ICPT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ICPT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ICPT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ICPT
DTCC (dtcc.com): http://search2.dtcc.com/?q=Intercept+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Intercept+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Intercept+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ICPT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ICPT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ICPT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ICPT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ICPT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ICPT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ICPT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ICPT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ICPT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ICPT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ICPT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ICPT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ICPT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ICPT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ICPT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ICPT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ICPT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ICPT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ICPT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ICPT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ICPT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ICPT



$ICPT DD Notes ~ http://www.ddnotesmaker.com/ICPT

[osaffer]

http://www.prnewswire.com/news-releases/a-large-prevalent-population-and-the-lack-of-an-approved-therapeutic-highlight-lucrative-market-opportunity-in-nonalcoholic-steatohepatitis-300176002.html

[osaffer]

BofAMerrill+Lynch+Downgrades

http://www.streetinsider.com/Analyst+PT+Change/BofAMerrill+Lynch+Downgrades+Intercept+Pharmaceuticals+(ICPT)+to+Underperform/11010828.html

[osaffer]

Causes

http://charts.stocktwits.com/production/original_44632096.JPG?1446124868

[osaffer]

Morgan Stanley Target Price ...
http://www.streetinsider.com/Analyst+PT+Change/Intercept+Pharmaceuticals+(ICPT)+Price+Target+Lowered+to+$110+at+Morgan+Stanley/11014655.html

[osaffer]

This is the end for ICPT

You should think to an other alternative ...

Japan results are bad!

http://seekingalpha.com/arti
cle/3618526-premarket-biotech-digest-intercepts-setback-takeover-talks-amgens-q3 -results?auth_param=k1v6r:1b343dk:0994c643364cef69f599b313b10f81e4&uprof=45

http://www.americanbankingnews.com/2015/10/28/intercept-pharmaceutica ls-stock-rating-lowered-by-bank-of-america-icpt/

[oldsport]

wow... wildride in a few hours time...

[DewDiligence]

ICPT -16%/PM on phase-2 NASH data in Japanese patients: #msg-118050513.

[osaffer]

- Professor Stephen Harrison will detail the beneficial effects of Elafibranor (GFT505) on
cardiometabolic risk markers of NASH patients:
“BENEFICIAL EFFECTS OF THE DUAL PPAR ALPHA-DELTA AGONIST, GFT505, ON HEPATIC AND
CARDIOMETABOLIC MARKERS IN ADULT NASH PATIENTS” SA Harrison et al. (Abstract 162)
- Professor Arun Sanyal will analyze the hepatic and extra-hepatic responses linked to the
treatment of NASH by Elafibranor:
“THE HEPATIC AND EXTRA-HEPATIC PROFILE OF RESOLUTION OF STEATOHEPATITIS INDUCED
BY GFT-505” A Sanyal et al. (Abstract 2145)

[osaffer]

GENFIT ANNOUNCES ELAFIBRANOR PRESENTATIONS
AND PRESIDENTIAL PLENARY AT THE 2015 AASLD
ANNUAL MEETING
? The results of the GOLDEN-505 phase 2b study of Elafibranor in
NASH have been selected for an exclusive oral presentation
during the Presidential Plenary session.
? Additional data from the Phase 2b study will be described in oral
presentations as well as in a poster session.


http://www.genfit.com/wp-content/uploads/2015/10/2015.10.02-PR-GENFIT-AASLD-2015.pdf

[DewDiligence]

ICPT starts phase-3 NASH trial called REGENERATE: #msg-117301781.

[DewDiligence]

Should be a modest positive, IMO.

[TSmith4659]

Dew, one more question. How is the news about RPTP's PII going to affect ICPT? Should their failure be a positive for ICPT? Thanks, have a good day!


TS

[DewDiligence]

ICPT has some buyout vig, but not from GILD, IMO. GILD is already committed to its own multifaceted NASH program.

[TSmith4659]

Dew, do you think ICPT is a buyout candidate? Who would benefit the most from their technology, GILD? What is it worth at this point? I just started following, I appreciate your views. Thanks


TS

[osaffer]

Genfit

Presentation Morgan Stanley Event

http://www.genfit.com/wp-content/uploads/2015/09/2015.09.15-GENFIT-Overview.pdf

[osaffer]

Wait for Phase 3 design for Genfit

ICPT is game over ...

http://www.genfit.com/wp-content/uploads/2015/09/2015.09.15-GENFIT-Overview.pdf

[DewDiligence]

Phase-3 REGENERATE trial in NASH posted on clinicaltrials.gov:

https://clinicaltrials.gov/ct2/show/NCT02548351

Note the exclusion criteria—especially items 3, 5, 9, and 13.

[osaffer]

BRIEF-Genfit announces positive results from its NASH biomarker program

http://www.reuters.com/article/2015/09/15/idUSFWN11L00420150915?type=companyNews

[osaffer]

OCA is only for PBC not NASH


Look at this !

http://www.genfit.com/pipeline/elafibranor/#.dpuf

[osaffer]

Nothing...
I was just sharing information with the board, about a wonderful company based in Belgium.

The potential is wonderful !

We are here to make money, nothing else ...

[DewDiligence]

PDUFA date for OCA NDA in PBC is 2/29/16 (with priority review):

http://finance.yahoo.com/news/fda-grants-priority-review-intercepts-110500232.html

[DewDiligence]

What does the Tigenix phase-3 trial have to do with ICPT?

[osaffer]

Genfit is great ... But there is also TIGENIX

http://www.wmcactionnews5.com/story/29920070/biolife-solutions-customer%20-tigenix-phase-3-clinical-trial-meets-primary-endpoint

[osaffer]

Genfit: Are you going to come here now ?

[osaffer]

For sure ... it is Genfit's Time !!!

You can hope to multiple your bet by 10 !

[Hfbiotechinvest]

Morgan Stanley starts Intercept coverage with only 165 target price...
Lipidic profile of OCA in question... Time to change strategy and consider alternative - and safer - drugs?

http://news.investors.com/technology/081315-766405-icpt-stock-falls-on-morgan-stanley-report.htm?ven=rss&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed:%20InternetTechnologyRss%20

[osaffer]

http://seekingalpha.com/article/3332095-a-european-biotech-stock-basket-for-2015-an-update

[osaffer]

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)61198-9/fulltext

[osaffer]

FDA Expands Advice on Statin Risks

http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm

[osaffer]

http://www.nature.com/nrd/journal/v14/n7/full/nrd4667.html

You should access and read ...

Phase 3 for Genfit with less patients ... 1500

[DewDiligence]

ICPT submits NDA for OCA in PBC:

http://finance.yahoo.com/news/intercept-pharmaceuticals-submits-applications-u-200500920.html

Although PBC is the lead indication, it’s a small market that’s much less consequential to ICPT’s commercial success than the OCA program in NASH.